Downgrades

Lupin delivered yet another quarter of earnings outperformance vs street as well as our estimates, with the beat in 1QFY26 being driven by a higher gross margin.

In Q1FY26, PVR Inox’s revenue grew 23.4% YoY/ 17.5% QoQ, driven by successful Bollywood and Hollywood releases as well as initiatives like Blockbuster Tuesday and F&B combo offers.

Prudent Corporate Advisory Services (Prudent) has progressed well in terms of AUM growth aided by MTM, traction in SIP and growth in MFDs. AUM/gross SIP flows/MFD count clocked CAGR of 40%/20%/19% between FY20–25 and grew 13.9% QoQ / 27.7% YoY /12.8% YoY in Q1FY26, respectively.

PVR INOX reported strong YoY growth in Q1 FY26, with admissions up 12% to 34 mn, ATP rising 8% to Rs 254, and SPH hitting a record Rs 148 (up 10%). Ad revenue grew 17% to Rs 110cr, while adjusted revenue stood at Rs 1,488cr, EBITDA at Rs 114cr, and net loss narrowed to Rs 34cr. Despite losing 67 lakh admissions, the company saw strong footfalls aided by affordable pricing and weekday value offers. It maintained its Rs 400425cr FY26 capex guidance, including Rs 250260cr for new screens and Rs 7075cr for renovations. Net debt reduced to Rs 892cr. The capitallight strategy continues, with 20 screens added (14 under FOCO/asset-light) and 127 signed. "Blockbuster Tuesday" has driven higher weekday traffic, and...

Castrol India's revenue and EBITDA exceeded our expectations. Castrol's sales increased by 7% YoY, led by 8% YoY volume growth on the back of strong volume growth in the industrials segment (+13% YoY) and rural geographies (+12% YoY). Personal Mobility and CVs reported high single digit volume growth. EBITDA increased by 8% YoY to Rs3.5bn, with EBITDA margin expanding by 28bps YoY to 23.4%, primarily due to lower A&P spends and price hikes. Management remain focused on expanding the distribution network and deepening penetration in the Industrials segment. Castrol has gained 40bps...

Harsha Engineers (Harsha) delivered results above our estimates. Revenue, EBITDA and PAT grew by 6%, 1% and 5% respectively on YoY basis. Green shoots were seen in the way of improvement in industrial demand in Europe which led to 18% YoY revenue growth in Harsha Romania for the quarter. Harsha also witnessed healthy demand improvement for large sized cages as well. Positive signs were also seen in improving demand for bearing cages in India however auto demand remained sluggish. However the management asserted that it will take at least 2 quarters to consider this as a sustainable demand trend. The...

NCC Limited reported a muted financial performance for Q1 FY26, with consolidated revenue declining by 6.3% YoY to Rs52bn. PAT stood at Rs1.9bn, reflecting an 8.5% drop YoY. This decline was largely driven by execution delays and slower turnover, which echoed the concerns raised in Q3 FY25. Despite the revenue softness, EBITDA margins remained relatively stable at approximately 8.8%, aided by disciplined cost control and project management practices. EPS for the quarter came in at Rs3.06, compared to Rs3.34 in Q1 FY25. We maintain our rating to BUY, revising the target price to Rs247, valued at 12x FY27E EPS. A...

We recommend a BUY rating with a target price of Rs 2,500/share.

With a 15% upside potential from the CMP, we maintain our BUY rating on the stock.

We maintain our BUY recommendation on the stock with a target price of Rs 1,920/share, offering 27% upside from the current levels.

We maintain our HOLD on the stock and recommend a buy on dips strategy.

Quarterly Update Q1FY26

We reiterate BUY on Anant Raj, with an unchanged TP of Rs800. We visited the company’s new data center facilities in Panchkula (7MW capacity) and Manesar (21MW), in Haryana.

Aurobindo Pharma's (ARBP) Q1FY26 EBITDA of Rs16.1bn (down 1% YoY) was 5% below our estimate led by lower US sales. Resultant our FY26 and FY27E EPS stands reduced by 5-10%. The company has maintained its 20-21% OPM guidance for FY26E despite gRevlimid sales loss. We expect margins and revenues to improve from H2FY26/FY27 with ramp up in PenG facility, Vizag pant commercialization and launches in US. We believe ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars...

Alembic Pharma’s (Alembic) Q1FY26 result was in line with our expectations. Revenue growth was mainly driven by US (13% YoY) and ex-US international business (21% YoY). India growth was tepid at 4.7% YoY due to challenges in specialty portfolio (up 1% YoY) and slowdown in acute market.

Finolex Industries' (FIL) Q1FY26 result was below our estimates on key parameters. The company experienced modest growth in pipes and fittings volumes, despite a weak overall demand scenario, however, operating performance was muted mainly due to weaker realization on account of volatility in PVC prices. The management guided that the demand has shown high single-digit growth as of early August 2025. The company expects this high single-digit trend to continue and is hopeful of crossing double-digit growth for FY26. Net sales declined by 8.5% YoY to Rs10.4bn, while EBITDA came in at...

JK Paper Ltd.'s (JK Paper) Q1FY26 result was broadly in-line with estimates on net sales and EBITDA front, while net profit was below our forecast. The Company's core business in Paper and Paper Board continued to face headwinds from cheap imports resulting in depressed sales realization and ongoing high domestic wood prices weighed on operating margin. Despite this, JK Paper improved its profits on a sequential basis. The management believes that packaging conversion business is amongst the fastest growing segments in the Indian Paper and Packaging industry driven by growth in end use industries....

We maintain our BUY recommendation on the stock with a TP of Rs 1,400/share.

We continue to maintain our HOLD rating on the stock.